PP
XENE icon

PDT Partners’s Xenon Pharmaceuticals XENE Stock Holding History

PDT Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,451
Closed -$253K – 898
2020
Q4 		$253K Sell
16,451
-1,182
-7% -$13.8K 0.02% 579
2020
Q3 		$195K Sell
17,633
-12,046
-41% -$142K 0.01% 631
2020
Q2 		$372K Buy
29,679
+7,590
+34% +$96.6K 0.03% 479
2020
Q1 		$250K Buy
+22,089
New +$315K 0.02% 510
2018
Q4 		– Sell
-16,074
Closed -$212K – 518
2018
Q3 		$212K Sell
16,074
-1,763
-10% -$20.4K 0.01% 427
2018
Q2 		$164K Buy
+17,837
New +$111K 0.01% 483

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PDT Partners's XENE Position: Q1 2021 in Review

PDT Partners sold out of Xenon Pharmaceuticals (XENE) in Q1 2021, closing a stake of 16,451 shares — an estimated $253K sold.

PDT Partners first reported a position in XENE in Q2 2018 and held it in 6 quarters. The position peaked at $372K in Q2 2020. 91 funds tracked by Wall St. Rank hold XENE as of Q1 2021.

  • PDT Partners reported no remaining Xenon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • PDT Partners sold 16,451 Xenon Pharmaceuticals shares in Q1 2021, an estimated $253K.
  • PDT Partners first reported a position in Xenon Pharmaceuticals in Q2 2018 and held it in 6 quarters.
  • PDT Partners's Xenon Pharmaceuticals position peaked at $372K in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2021.

Based on PDT Partners's 13F filing for Q1 2021, filed 17 May 2021.